Mablink Bioscience
Country: France
Region: Lyon
Investors: Sofinnova Partners, Mérieux Equity Partners
Mablink Bioscience is a major European VC success story in cancer treatment. The company is well on its way toward achieving its goal: to bring new and better treatment options to cancer patients with unmet needs.
Mablink announced on 18 October 2023, that it was entering an agreement to be acquired by Eli Lilly. The transaction was completed on 1 December 2023 by Eli Lilly.
Mablink Bioscience is a biotechnology company developing the next generation of an emerging class of cancer drugs called antibody-drug conjugates (ADCs). Mablink’s patented hydrophilic drug-linker technology, PSARLink™, enables the design of homogeneous, plasma-stable, next generation ADCs with high DAR (drug-to-antibody ratio) while maintaining excellent pharmacological properties and tolerability
We are grateful to Sofinnova Partners, Mérieux Equity Partners, and all of our earliest supporters, who believed in our approach. Our team and our technology received a huge endorsement when Eli Lilly made their offer, and our combined expertise should lead to faster delivery of transformative cancer therapies to patients in need.
35
employees
€31M
raised in Series A, in 2022
2024
planned start of clinical trials
As an investor, it is rare to find out so quickly that you made a great choice. Jean-Guillaume and his team built a fantastic company around breakthrough technology, executing perfectly all along the way. Congratulations to them - and to Eli Lilly.
Key achievements
Founded 2018
2019 received French Tech Seed label
2019 awarded R2B Onco Trophy
2019 pre-clinical proofs trough incubation within Pulsalys
2019 CLARA proof of Concept for ADC platform
2021 licencing agreement with Emergence Tx to further develop PSARlink™ drug-linker technology
2023 Presenting preclinical data for Lead ADC Candidate MBK-103
2023 Agreement to be acquired by Eli Lilly
Funding history
Seed €4M from syndicate of private investors in 2021
Series A €31M led by Sofinnova Partners in 2022
Employment impact
Mablink has had its headquarters in Lyon since 2023, with labs and offices for its 35 employees spread over 2,000 square meters
Eli Lilly wants to continue to increase the capacity of the Mablink building, which is effectively its first oncology site in France
The number of employees will continue to increase
Find out more
Investors
